You are here

Sanj K. Patel - Chairman & Chief Executive Officer

Sanj K. Patel is the Chairman and CEO of Kiniksa Pharmaceuticals, which was formed in 2015 to develop therapies for patients with devastating diseases and unmet medical need. He brings more than 25 years of experience in the pharmaceutical and biotech industries and has a combination of scientific, clinical and commercial skills. Sanj K. Patel created Synageva in June 2008 to focus on rare diseases, and designed and initiated its lead program (Kanuma®) for Lysosomal Acid Lipase Deficiency (LAL Deficiency) in July 2008. Kanuma was approved globally in 2015 as the first therapy for patients suffering from LAL Deficiency. He took the company public on the NASDAQ Global Market in November 2011 and raised over $1 billion in capital in less than 5 years. In June 2015, Synageva was sold to Alexion Pharmaceuticals for $9.5B (including cash), which represented the highest premium ever paid for a biotech company valued over $5B.

Prior to Synageva, he was at Genzyme Corporation (1999-2008) where most recently he was the head of U.S. Sales, Marketing and Commercial Operations for Genzyme Therapeutics franchise and led the U.S. launch of Myozyme®, in addition to sales and marketing responsibility for Cerezyme®, Fabrazyme® and Aldurazyme®. Previously, Sanj held several cross-functional senior leadership roles at Genzyme, including Vice President, Clinical Research and Head of the Global Clinical Research Operations Council for all Genzyme divisions, including Therapeutics, Oncology and Transplant. He was responsible for clinical operations and development for all cross-business Genzyme products and was instrumental in the path to commercialization of several treatments. Notably, Sanj led the Fabrazyme® clinical operations team and development program to FDA approval in April 2003. Prior to Genzyme, Sanj held roles in clinical research and commercial operations with increasing levels of responsibility at Burroughs Wellcome, Hoechst Marrion Roussel and Fujisawa/Otsuka Pharmaceuticals. Sanj obtained his BSc with Honors in Biotechnology from the University of the South Bank, London. He completed his management and business studies at Ealing College, London and his Pharmacology research program at the Wellcome Foundation. Sanj is a member of the Board of Directors for Syros Pharmaceuticals and BioCryst Pharmaceuticals, both publicly traded biotechnology companies. He is also the founder and director of the Sanj K. Patel and Family Foundation, a philanthropic organization that supports various charities supporting patients with rare and devastating diseases.

Stephen Mahoney - President & Chief Operating Officer

Steve Mahoney is Kiniksa’s President and Chief Operating Officer and is responsible for overseeing all operational aspects of the company, including advancement of our existing programs.  Steve’s industry experience consists of a variety of commercial, operational and legal roles where he has successfully built teams in multiple functional areas and consistently delivered value creating results.  He was most recently the Chief Commercial Officer of Synageva Biopharma where he was responsible for Synageva’s global commercial operations resulting in the company’s launch readiness for its lead program (Kanuma®).  During his tenure at Synageva, Steve had roles of increasing responsibility including Senior Vice President, United States and European Commercial Operations; Vice President, European Business Operations & Chief Legal Officer; and Vice President, General Counsel & Corporate Development.  In addition to building and leading Synageva’s commercial operations teams in the United States, Europe, LATAM and JAPAC, Steve had responsibility for functional areas such as Global Sales Operations & Business Analytics, Commercial Supply Chain & Logistics, Global Procurement, Patient Services, Sales Training, Legal and Corporate Development. Prior to Synageva, Steve was a commercial attorney for Genzyme Corporation where he was responsible for all legal and healthcare compliance issues for multiple business units.  He then served as Genzyme’s Regional Legal Director for the Asia Pacific region based in Singapore. In Asia Pacific, Steve was responsible for the legal and corporate development aspects for all of Genzyme’s products and businesses in the region.  Prior to Genzyme, Steve was a corporate attorney with Mintz, Levin, Cohn, Ferris, Glovesky and Popeo, LLP, a large international law firm headquartered in Boston, MA.  He holds a Masters in Business Administration (MBA) from Boston College’s Carroll School of Management, a Juris Doctor (JD) from Boston College Law School and a Bachelor of Arts from Colorado College. 

Carsten Boess - Chief Business Officer

Carsten Boess is the Chief Business Officer of Kiniksa. He brings more than 25 years of financial operations and management experience in the life sciences industry with diversified experience across a broad field of areas both in the United States and internationally. He joined Synageva in May 2011 as Senior Vice President and Chief Financial Officer. He played a key role in Synageva becoming a public company on the NASDAQ Global Market in November 2011 and supported fundraising efforts for multiple secondary offerings. Prior to joining Synageva, Carsten served in the roles of Chief Financial Officer and Vice President, International of Insulet Corporation, respectively (June 2006-2011) and has also served in the following capacities: Chief Financial Officer of Alexion Pharmaceuticals, Inc., Executive Vice President of Finance for Serono, Inc. and Vice President Finance, International Operations, Novo Nordisk. Carsten has significant international experience having served as head of finance of companies in the United States, Denmark, China, Switzerland, and France.  He also headed the expansion of Insulet’s business internationally in the role of Vice President, International. Carsten earned a Bachelor’s and Master’s degree in economics and finance from the University of Odense, Denmark.

Chris Heberlig - Chief Financial Officer

Chris Heberlig is the Chief Financial Officer of Kiniksa with responsibility for finance, treasury, tax and information technology.  He has more than 20 years of experience in financial management and operations, primarily focused on the life sciences industry. Prior to joining Kiniksa, Chris spent over 6 years at Synageva BioPharma Corp. in roles of global financial and operational leadership, most recently serving as Senior Vice President of Finance and Business Operations. He played a key role in Synageva becoming a public company on the NASDAQ Global Market in November 2011, supported fundraising efforts for over $1 billion in new capital and oversaw financial operations expanding to more than 15 countries to support the global development and launch preparations for Kanuma®He also lead strategic tax planning for the company including overseeing the transfer of tax and intellectual property assets to Europe. At Synageva, his most recent responsibilities included global financial operations, facilities, as well as program management. Prior to Synageva, he held senior financial management positions at Panacos Pharmaceuticals Inc. and EPIX Pharmaceuticals Inc., both publicly traded biotechnology companies. Chris began his career at PricewaterhouseCoopers where he worked with a variety of public and private audit clients. He holds a master's degree in business administration from Boston University and a bachelor of arts in economics from St. Lawrence University. Chris is also a Certified Public Accountant.

Tom Beetham - Chief Legal Officer & Corporate Development

Tom Beetham is Kiniksa's Chief Legal Officer and is also responsible for the company’s corporate development activities.  Tom has over 15 years of transactional, business and legal experience in the life science industry.  Most recently, Tom was the Chief Legal Officer and Senior Vice President of Corporate Development for Synageva BioPharma Corp.  At Synageva, in addition to leading the legal department, he was responsible for business development activities and was instrumental to the success of the Alexion acquisition.  Prior to joining Synageva in 2013, Tom was the General Legal Counsel for New England Biolabs, Inc., where he was responsible for all legal matters and a member of Biolabs' Global Business Development team. Prior to Biolabs, Tom was with Genzyme Corporation where he was the lead corporate attorney responsible for Genzyme's Hematology/Oncology and Multiple Sclerosis products. Before Genzyme, Tom was a corporate, securities and transactional attorney with the law firm of Palmer & Dodge, LLP in Boston, Massachusetts. He received his JD and MBA degrees from Boston College, and a BA from the University of Rochester

John Paolini – Chief Medical Officer

John Paolini is Kiniksa’s Chief Medical Officer.  His over 25 years of experience spans from basic biological/medical science through all phases of clinical development and regulatory strategy for small molecules and biologics.  Dr. Paolini was most recently Clinical Research Head of the Cardiovascular and Metabolic Diseases Research Unit at Pfizer Inc., where he was responsible for bringing forward programs in diabetes, heart failure, lipids, and metabolic liver disease from preclinical through early clinical development and proof of concept. Dr. Paolini previously served as Chief Medical Officer of Cerenis Therapeutics in France, a publicly traded company on the Euronext exchange.  He was responsible for designing and executing clinical trials and regulatory strategy for a portfolio of products relating to HDL and reverse lipid transport and also played an instrumental role in the company’s capital raising efforts including its initial public offering.   Before moving to France, Dr. Paolini was Global Clinical Leader at Bayer HealthCare Pharma, where he was responsible for the Phase III program, NDA filing, and launch of Xarelto in atrial fibrillation as well as Xarelto Life Cycle Management. He started in the pharmaceutical industry at Merck & Co., Inc., in Cardiovascular Clinical Research and Clinical Pharmacology, leading programs in thrombosis and dyslipidemia that spanned the early and late stage portfolio, including Zocor and Aggrastat, the Vytorin, Zetia, and Tredaptive clinical development programs and NDAs, as well as in-licensing activities in cardiovascular disease.

Dr. Paolini obtained an M.D., Ph.D. from Duke University, where his Ph.D. work focused on the protein chemistry of immune mediators.  He subsequently completed a residency in Internal Medicine and a fellowship in Cardiovascular Medicine at the Brigham and Women’s Hospital, including a postdoctoral fellowship at the Massachusetts Institute of Technology researching the role of inflammatory mediators in vascular disease and restenosis. He received Board certification in Internal Medicine and Cardiology and is a Fellow of the American College of Cardiology.   He was a member of the clinical faculty at the University of Pennsylvania as a Clinical Associate and served as an attending physician for 10 years, precepting cardiology fellows in the HUP outpatient cardiology clinic.  He has authored more than 75 peer-reviewed journal articles and abstracts.  He received a Bachelor of Arts, summa cum laude and a Bachelor of Science, summa cum laude from Tulane University.

Christine Maurer – Senior Vice President, Program Management

Christine Maurer serves as Senior Vice President of Program Management at Kiniksa and brings over 18 years of experience in the management of multi-million dollar R&D portfolio programs in the life sciences industry.  Most recently, Christine was Vice President of Business Operations at Synageva where she led the Company Sponsored Study to accelerate the widespread screening and identification of patients with LAL Deficiency in 100+ centers globally.  Prior to joining Commercial Operations, Christine served as Vice President of Program Management and Operations and led the Kanuma program for LAL Deficiency to successful IND/CTA filings, completion of a global Phase 1/2 trial and initiation of the Pivotal Phase 3 ARISE trial and was a key contributor to building the rare disease product portfolio.  Prior to Synageva, Christine held roles of increasing responsibility in Project, Program & Alliance Management at Biogen Idec, Molecular Insight Pharma (Progenics), Globomax (ICON) and US Surgical Corporation (Medtronic). She also served as a Project Management Consultant for Integrated Project Management Corporation.  Christine holds a Bachelor’s in Business Administration from Pace University in New York and a Master’s of Science in Project and Program Management from Brandeis University in Massachusetts.  

Gregory Grabowski - Chief Scientific Officer

Greg Grabowski is a leading authority in genetic diseases and metabolic disorders. His research career, particularly in lysosomal storage diseases, had been funded by the National Institutes of Health for over 35 years. Dr. Grabowski received his BA (Mathematics) and MD, both with honors, from the University of Minnesota, where he also completed his residency in Pediatrics and fellowship in Human Genetics. In 1979, he moved his established research and clinical programs to New York City and the Mount Sinai School of Medicine, where he developed the world’s largest clinic for patients afflicted with Gaucher disease and other lysosomal diseases. He established basic research and diagnostic laboratories for genetic diseases as well as the first treatment center for enzyme therapy in Gaucher disease. Following a highly productive 13.5 years, he became the A. Graeme Mitchell Chair of Human Genetics, and Director of Human Genetics (DHG) at the Cincinnati Children’s Hospital Medical Center (CCHMC) as well as Professor in the Departments of Molecular Genetics and Biochemistry, and Pediatrics, at the University of Cincinnati College of Medicine. In these positions, he created the clinical, educational, diagnostic, and research infrastructure for the DHG and recruited ~30 faculty. He has published over 325 scholarly works on the basic and clinical sciences of lysosomal storage diseases, including Gaucher, Fabry, Pompe, and the Mucopolysaccharide diseases, for which he has received national and international awards. He has continuously served on committees of the National Institutes of Health, national and state governments, and several philanthropic and patient foundations, including the Project Hope/Genzyme Gaucher Initiative (2000- present) of which he was the founding chair of the expert medical committee. He is a member of the American Society for Clinical Investigation, the American Association of Physicians, and other scientific societies. He has served as President of the Society for Inherited Metabolic Diseases. He was an active consultant to Genzyme Corportation (1990-2013) in multiple research and clinical capacities. In 2014, after 21.5 years at CCHMC, Dr. Grabowski joined Synageva BioPharma as their Chief Scientific Officer to continue the pursuit of therapies for rare, devastating, inherited diseases. Now, he holds positions of Professor Emeritus of Pediatrics and Genetics at CCHMC, and is a Consultant for and/or member of Scientific Advisory Boards for several biotech companies, including Alexion Pharmaceuticals, Lysosomal Therapeutics, Inc., and elpidera (a moderna venture), and is Chief Scientific Officer of Kiniksa Pharmaceuticals.

Brendan Classon - Vice President, Research

Brendan Classon serves as Kiniksa’s Vice President, Research. Brendan has 17 years of immunology R&D experience in the large pharmaceutical and biotechnology sectors. Most recently, as Head of External Innovation Immunology (Global) at Sanofi, he was responsible for coordinating and directing scientific assessments of external preclinical and clinical assets for in-licensing and development in autoimmune disease. Prior to Sanofi, he was Director of Biopharmaceuticals Innovation Sourcing at Novo Nordisk, where he also led scientific evaluation of external opportunities. Before joining Novo Nordisk, he led Inflammation & Immune Diseases research at Regeneron Pharmaceuticals, Inc., where he directed preclinical pharmacology activities for program targets, including Dupixent® (dupilumab) to support clinical development opt-in proposals and regulatory submissions. Prior to Regeneron, he had research positions at Bristol-Myers Squibb, Peptimmune and Millennium Pharmaceuticals. Brendan graduated from Monash University, Australia with a Bachelor of Science (Honors, First Class) degree and obtained the degree of Doctor of Philosophy in Immunology from The University of Melbourne, Australia. After completing his post-doctoral training at The University of Oxford, UK, he held academic positions in Australia at the Walter & Eliza Hall Institute of Medical Research and at Monash University, prior to joining industry in 2001.

Dawn McCollough - Vice President, Clinical Operations

Dawn McCollough serves as Kiniksa’s Vice President, Clinical Operations and is responsible for the timely and quality execution of global clinical trial programs. Dawn’s 23-year career includes executive clinical and business operations roles in which she has led the development and execution of strategic plans.  These have included the successful launch of new products and the expansion of existing programs. Dawn has overseen clinical trials involving thousands of patients across numerous indications and stages of development. Dawn joins Kiniksa from XBiotech where she was Vice President of Clinical Operations. Prior to that, Dawn served as Head of Medical Research Operations at Biogen, Inc., where she led the Medical Research team, which included the company’s Clinical Trial Review Committee for late-phase research. Prior to Biogen, Dawn was head of the Global Monitoring Organization for North America at Novartis Vaccines and Diagnostics, Inc., based in Cambridge, MA. Dawn began her Novartis career in their Vaccines and Diagnostics division in Siena, Italy, as Global Head of Clinical Trial Governance.  This post involved extensive experience in Europe and Asia Pacific.  Throughout her career, she has held roles of increasing responsibility in Project, Program and Clinical management and has been recognized consistently for her high performance and was chosen as a top Women’s Leader.  Dawn holds a Bachelor of Arts in History from Temple University and attended the Post-Baccalaureate Pre-Health programs at both Philadelphia College of Pharmacy & Science and University of Pennsylvania.

Dave Nichols – Vice President, CMC and Technical Operations

Dave Nichols brings nearly three decades of CMC (Chemistry, Manufacturing and Controls) experience in the field of Biologics.  Dave has lead internal teams and various CDMOs responsible for process development, GMP operations, tech transfer efforts from Research to CMC and from CMC to GMP operations, on-going technical support for commercially- approved products, and analytical and quality control teams.   Dave has lead teams that have successfully brought four biologic programs from early development through commercial approval. Dave has created CMC organizations from scratch at Tesaro, a division of Teva and at Shire. These teams were widely recognized as effective, efficient, proactive and with a deep level of scientific acumen.

Dave also brings significant experience with regulatory filings per phase and agency.  He represented Shire as Biologics lead for FDA advisory committee meetings.  Met with EMEA and FDA agents on multiple occasions to discuss drug product approval. Led the development team in PAI (pre-approval inspection) readiness and in meetings with the various agency inspectors.  Prepared and presented a series of summary talks to the respective agencies as to the complexities of biologics development.